Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cefamandole + gentamicin is a combination of two antibiotics used primarily for the treatment of severe bacterial infections, especially those caused by gram-negative organisms. Cefamandole is a second-generation cephalosporin (beta-lactam) antibiotic that acts by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins, leading to cell lysis and death. Gentamicin is an aminoglycoside antibiotic that binds to the 30S subunit of bacterial ribosomes, inhibiting protein synthesis and resulting in bactericidal activity. The combination exploits synergistic effects between beta-lactams and aminoglycosides, enhancing efficacy against certain pathogens and reducing relapse rates compared to monotherapy. This regimen has been used successfully in conditions such as pyelonephritis, septicemia, respiratory tract infections, urinary tract infections, skin/soft tissue infections, bone/joint infections, and peritonitis[1][2][6][7][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cefamandole + gentamicin.